MK-677 Dosage: Oral Ranges & the Safety Picture

---

Educational information, not medical advice. The doses on this page come from approved labels, published studies and, where no study exists, amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.

The short version

MK-677 is a non-peptide small molecule that activates the ghrelin receptor (GHS-R1a), prompting the pituitary to release growth hormone in a roughly natural, pulsatile pattern and raising IGF-1. It is grouped with peptides by convention — clinics prescribe it alongside them — but chemically it is a conventional orally active drug. Because it is taken by mouth, there is no reconstitution and no injection: dosing is simply a daily oral amount. And because it is unapproved, there is no official dose, titration, or maximum.

Doses used in research

The published human studies give the most reliable anchor for what "a dose" means here, even though none support self-use:

The 12-month trial is the most instructive: the lean-mass increase did not translate into measurable strength or functional improvement, while fasting glucose rose and insulin sensitivity worsened. In other words, the headline "muscle" effect was partly water and came with a metabolic cost.

What community use reports

Community use most commonly reports 10–25 mg once daily, often taken at night because some users find the appetite and drowsiness effects easier to manage during sleep, and because GH release is naturally concentrated in slow-wave sleep. These are descriptive observations, not a recommendation. Going above ~25 mg tends to amplify the side effects — hunger, fluid retention, and rising blood sugar — without a clear benefit.

Timing and half-life

MK-677 has a terminal half-life of roughly 4–8 hours, but its effect on IGF-1 is sustained across a full 24-hour interval, which is why once-daily dosing is typical regardless of the time chosen. The drug's oral bioavailability is high for an orally dosed molecule. You can explore how a once-daily oral compound behaves over a dosing cycle with our Half-Life Visualizer, and check potential conflicts with other medicines using the Interaction Checker — bearing in mind these are educational tools, not a substitute for clinical care.

Why dose discipline matters here

Three side effects are dose-related and worth understanding before reading any protocol. Appetite can be intense, especially in the first 4–6 weeks. Fluid retention and mild edema are common early and usually settle. Most importantly, fasting glucose and insulin resistance tend to rise, which is why people with diabetes or prediabetes are repeatedly flagged as poor candidates. Layered on top is the early-terminated heart-failure trial that anchors the FDA's safety position. None of this is managed by "starting low" alone — it reflects the pharmacology of sustained GH/IGF-1 elevation.

Where MK-677 stands legally

MK-677's regulatory path differs from injectable peptides like BPC-157 and TB-500. Merck developed it in the 1990s and discontinued the program in 1999. On October 29, 2024 the PCAC voted 13 to 1 against adding ibutamoren mesylate to the 503A bulks list (FDA's minutes), and FDA lists it in 503A and 503B Category 2 for significant safety risks (lists re-read September 26, 2026) — so unlike BPC-157 and TB-500, its compounding door is closed rather than pending. In a December 19, 2025 warning letter, FDA reported finding undeclared ibutamoren in children's "growth" products sold as supplements and stated that ibutamoren is excluded from the dietary-supplement definition (FD&C Act section 201(ff)(3)(B)(ii)). It is not a DEA-controlled substance, and is typically sold as a "research chemical." Meanwhile, LUM-201 — the same molecule under Lumos Pharma — is in Phase 2 trials for pediatric growth-hormone deficiency, the one active clinical development path. See the Regulatory Status Tracker for details.

Frequently asked questions

Morning or night?

Either works pharmacologically because the IGF-1 effect spans 24 hours. Night dosing is common anecdotally to align with natural GH pulses and to sleep through the appetite bump, but this is preference, not evidence.

Should the dose be "cycled"?

Community protocols often run blocks of weeks to months. There is no trial-based schedule, and the metabolic effects (glucose, insulin) are a reason some argue against continuous long-term use — but this remains unsettled without long-term human safety data.

Is the lean mass "real" muscle?

Partly water. The 12-month trial increased fat-free mass without improving strength or function, so the visible change overstates any performance benefit.

---

Sources

1. Chapman IM, et al. "Stimulation of the GH–IGF-I axis by daily oral MK-677 in healthy elderly subjects." J Clin Endocrinol Metab. 1996;81:4249–4257.
2. Nass R, et al. "Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial." Ann Intern Med. 2008;149:601–611.
3. U.S. FDA — PCAC minutes on ibutamoren mesylate (October 29, 2024: 1 for, 13 against); 503A category list (updated May 14, 2026) and Category 2 page (current as of April 22, 2026); warning letter to AgeBox Inc (MARCS-CMS 718252), December 19, 2025.

Medical disclaimer: Education only, not medical advice. MK-677 (ibutamoren) is not approved for human use. Dosing figures reflect research and community reports, not a recommendation. Do not self-administer; consult a licensed clinician. The only verified-safe path to treatment is an FDA-approved medicine under a clinician's supervision.